July 2022
1. RODVOLD KA, Gotfried MH, Gupta V, Ek A, et al
   Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
   Antimicrob Agents Chemother. 2022;66:e0059022.
   

   >> Share

   
   
2. WATSON JA, Kissler SM, Day NPJ, Grad YH, et al
   Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies.
   Antimicrob Agents Chemother. 2022;66:e0019222.
   

   >> Share

   
   
3. CHECKMAHOMED L, Carbonneau J, Du Pont V, Riola NC, et al
   In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
   Antimicrob Agents Chemother. 2022;66:e0019822.
   

   >> Share

   
   
4. ICHO S, Rujas E, Muthuraman K, Tam J, et al
   Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
   Antimicrob Agents Chemother. 2022;66:e0043922.
   

   >> Share

   
   June 2022
5. LEEGWATER E, Moes DJAR, Bosma LBE, Ottens TH, et al
   Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
   Antimicrob Agents Chemother. 2022;66:e0025422.
   

   >> Share

   
   
6. PITTS J, Li J, Perry JK, Du Pont V, et al
   Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
   Antimicrob Agents Chemother. 2022;66:e0022222.
   

   >> Share

   
   March 2022
7. DONG R, Jiang L, Yang T, Wang C, et al
   Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.
   Antimicrob Agents Chemother. 2022;66:e0204521.
   

   >> Share

   
   
8. CHEN J, Dai L, Kendrick S, Post SR, et al
   The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
   Antimicrob Agents Chemother. 2022;66:e0239521.
   

   >> Share

   
   
9. PARK AYJ, Tran DQ, Schaal JB, Wang M, et al
   Preclinical Pharmacokinetics and Safety of Intravenous RTD-1.
   Antimicrob Agents Chemother. 2022;66:e0212521.
   

   >> Share

   
   
10. BAGHDADI J, Bejo S, Harris A
    Reply to Casalini et al., "Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution".
    Antimicrob Agents Chemother. 2022;66:e0233221.
    

    >> Share

    
    
11. CASALINI G, Pozza G, Giacomelli A, Antinori S, et al
    Bacterial Coinfections in COVID-19 Patients without a Positive Microbiologic Result: a Word of Caution.
    Antimicrob Agents Chemother. 2022;66:e0229621.
    

    >> Share

    
    
12. HICKERSON BT, Adams SE, Barman S, Miller L, et al
    Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression.
    Antimicrob Agents Chemother. 2022 Mar 9:e0000922. doi: 10.1128/aac.00009.
    

    >> Share

    
    February 2022
13. MERCHANTE N, Carcel S, Garrido-Gracia JC, Trigo-Rodriguez M, et al
    Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.
    Antimicrob Agents Chemother. 2022;66:e0210721.
    

    >> Share

    
    
14. MEUNIER T, Desmarets L, Bordage S, Bamba M, et al
    A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses.
    Antimicrob Agents Chemother. 2022;66:e0158121.
    

    >> Share

    
    January 2022
15. DINESH KUMAR N, Ter Ellen BM, Bouma EM, Troost B, et al
    Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells.
    Antimicrob Agents Chemother. 2022;66:e0154321.
    

    >> Share

    
    November 2021
16. TIETJEN I, Cassel J, Register ET, Zhou XY, et al
    The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
    Antimicrob Agents Chemother. 2021;65:e0077221.
    

    >> Share

    
    October 2021
17. BAGHDADI JD, Coffey KC, Adediran T, Goodman KE, et al
    Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.
    Antimicrob Agents Chemother. 2021;65:e0134121.
    

    >> Share

    
    
18. LI Y, Qi L, Bai H, Sun C, et al
    Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
    Antimicrob Agents Chemother. 2021;65:e0106321.
    

    >> Share

    
    September 2021
19. SCHOOLEY RT, Carlin AF, Beadle JR, Valiaeva N, et al
    Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
    Antimicrob Agents Chemother. 2021;65:e0115521.
    

    >> Share

    
    
20. SHAH S, Ackley TW, Topal JE
    Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count?
    Antimicrob Agents Chemother. 2021;65:e0104521.
    

    >> Share

    
    
21. YAN VC, Muller FL
    Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.
    Antimicrob Agents Chemother. 2021;65:e0111721.
    

    >> Share

    
    August 2021
22. PASCUA PNQ, Jones JC, Marathe BM, Seiler P, et al
    Baloxavir treatment delays influenza B virus transmission in ferrets and results in limited generation of drug-resistant variants.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0113721. doi: 10.1128/AAC.01137.
    

    >> Share

    
    
23. GABORIT B, Dailly E, Vanhove B, Josien R, et al
    Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
    Antimicrob Agents Chemother. 2021;65:e0123721.
    

    >> Share

    
    
24. LI R, Liclican A, Xu Y, Pitts J, et al
    Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells.
    Antimicrob Agents Chemother. 2021;65:e0060221.
    

    >> Share

    
    
25. GAMMELTOFT KA, Zhou Y, Duarte Hernandez CR, Galli A, et al
    Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0268020.
    

    >> Share

    
    
26. HANSON BM, Dinh AQ, Tran TT, Arenas S, et al
    Candida auris Invasive Infections During a COVID-19 Case Surge.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0114621. doi: 10.1128/AAC.01146.
    

    >> Share

    
    July 2021
27. GOMIS-FONT MA, Pitart C, Del Barrio-Tofino E, Zboromyrska Y, et al
    Emergence of Resistance to Novel Cephalosporin-beta-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.
    Antimicrob Agents Chemother. 2021;65:e0008921.
    

    >> Share

    
    
28. LIMONTA D, Dyna-Dagman L, Branton W, Mancinelli V, et al
    Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65:e0049121.
    

    >> Share

    
    
29. WU X, Li N, Wang G, Liu W, et al
    Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Antimicrob Agents Chemother. 2021;65:e0035021.
    

    >> Share

    
    June 2021
30. MANTLO EK, Paessler S, Seregin A, Mitchell A, et al
    Luminore CopperTouch Surface Coating Effectively Inactivates SARS-CoV-2, Ebola Virus, and Marburg Virus In Vitro.
    Antimicrob Agents Chemother. 2021;65:e0139020.
    

    >> Share

    
    
31. RAMIREZ S, Fernandez-Antunez C, Galli A, Underwood A, et al
    Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Antimicrob Agents Chemother. 2021;65:e0009721.
    

    >> Share

    
    May 2021
32. WANG L, Zhu Q, Xiang K, Zhang Y, et al
    Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    March 2021
33. MENGUAL-CHULIA B, Alonso-Cordero A, Cano L, Del Mar Mosquera M, et al
    Surveillance of Influenza A resistance to polymerase complex inhibitors by whole genome analysis, 2016-17, 2017-18 and 2018-19 Seasons, Eastern Spain.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.02718.
    

    >> Share

    
    
34. YAN VC, Muller FL
    Remdesivir for COVID-19: Why Not Dose Higher?
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
35. DORGHAM K, Neumann AU, Decavele M, Luyt CE, et al
    Considering Personalized Interferon Beta Therapy for COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
36. JUNEJA K, Humeniuk R, Porter D, Cao H, et al
    Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?"
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
37. DAVOUDI-MONFARED E, Khalili H
    Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
38. GOOD SS, Westover J, Jung KH, Zhou XJ, et al
    AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
39. KUO CJ, Chao TL, Kao HC, Tsai YM, et al
    Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
40. MAY M, Chang M, Dietz D, Shoucri S, et al
    Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
41. TOMITA Y, Takeda M, Matsuyama S
    The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.00020.
    

    >> Share

    
    February 2021
42. KORMAN TM
    Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
43. HOLLAND TL
    Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
44. TE VELTHUIS AJW, Zubkova TG, Shaw M, Mehle A, et al
    Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02605.
    

    >> Share

    
    
45. MARTINEZ MA
    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    

    >> Share

    
    January 2021
46. XU Y, Barauskas O, Kim C, Babusis D, et al
    Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    
47. ACKLEY TW, McManus D, Topal JE, Cicali B, et al
    A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
    Antimicrob Agents Chemother. 2021;65.
    

    >> Share

    
    December 2020
48. ALEISSA MM, Silverman EA, Paredes Acosta LM, Nutt CT, et al
    New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
    Antimicrob Agents Chemother. 2020;65.
    

    >> Share

    
    
49. VANDERLINDEN E, Van Winkel N, Naesens L, Van Damme EJM, et al
    In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA and UDA as Inhibitors of Influenza a and B Virus Replication.
    Antimicrob Agents Chemother. 2020 Dec 7. pii: AAC.01732.
    

    >> Share

    
    November 2020
50. SUZUKI S, Nguyen CT, Ogata-Nakahara A, Shibata A, et al
    Efficacy of a cap-dependent endonuclease inhibitor and neuraminidase inhibitors against H7N9 highly pathogenic avian influenza virus causing severe viral pneumonia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01825.
    

    >> Share

    
    
51. MCCULLOUGH PA
    Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
52. YAN VC, Muller FL
    Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
53. LE MP, Le Beller C, Le Hingrat Q, Jaquet P, et al
    Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity".
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
54. DOI Y, Hibino M, Hase R, Yamamoto M, et al
    A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    October 2020
55. LE MP, Le Hingrat Q, Jaquet P, Wicky PH, et al
    Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
56. BUEHRLE DJ, Decker BK, Wagener MM, Adalja A, et al
    Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    August 2020
57. FERNANDEZ-CRUZ A, Ruiz-Antoran B, Munoz-Gomez A, Sancho-Lopez A, et al
    A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
58. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    

    >> Share

    
    July 2020
59. GORDY JT, Mazumdar K, Dutta NK
    Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
60. DANION F, Ruch Y, Fourtage M, Kaeuffer C, et al
    The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
61. SALGADO-BENVINDO C, Thaler M, Tas A, Ogando NS, et al
    Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
62. DAVOUDI-MONFARED E, Rahmani H, Khalili H, Hajiabdolbaghi M, et al
    Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01061.
    

    >> Share

    
    
63. MARZOLINI C, Stader F, Stoeckle M, Franzeck F, et al
    Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Antimicrob Agents Chemother. 2020 Jul 8. pii: AAC.01177.
    

    >> Share

    
    
64. MARATHE BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, et al
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00284.
    

    >> Share

    
    
65. MARTINEZ MA
    Clinical trials of repurposed antivirals for SARS-CoV-2.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.01101.
    

    >> Share

    
    June 2020
66. SOFTIC L, Brillet R, Berry F, Ahnou N, et al
    Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
67. JEON S, Ko M, Lee J, Choi I, et al
    Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    May 2020
68. HOFFMANN M, Schroeder S, Kleine-Weber H, Muller MA, et al
    Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
69. LI H, Zhou Y, Zhang M, Wang H, et al
    Updated Approaches against SARS-CoV-2.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
70. LIM JJ, Nilsson AC, Silverman M, Assy N, et al
    A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A infection.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00352.
    

    >> Share

    
    
71. ADAMS SE, Lugovtsev VY, Kan A, Bovin NV, et al
    Laninamivir-Interferon-lambda1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly Than Laninamivir Alone.
    Antimicrob Agents Chemother. 2020 May 11. pii: AAC.00301.
    

    >> Share

    
    April 2020
72. KOSHIMICHI H, Retout S, Cosson V, Duval V, et al
    Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00119.
    

    >> Share

    
    
73. ZHAO L, Yan Y, Dai Q, Li X, et al
    Development of Novel Anti-influenza Thiazolides with Relatively Broad-spectrum Antiviral Potentials.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00222.
    

    >> Share

    
    
74. NGUYEN CT, Suzuki S, Itoh Y, Ishigaki H, et al
    Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
    Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561.
    

    >> Share

    
    March 2020
75. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    

    >> Share

    
    January 2020
76. BROADBENT L, Parke HG, Ferguson LJ, Millar A, et al
    Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    
77. DEVINCENZO J, Tait D, Efthimiou J, Mori J, et al
    A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    Antimicrob Agents Chemother. 2020;64.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share